BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 18596579)

  • 21. Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry.
    Hopkin RJ; Cabrera GH; Jefferies JL; Yang M; Ponce E; Brand E; Feldt-Rasmussen U; Germain DP; Guffon N; Jovanovic A; Kantola I; Karaa A; Martins AM; Tøndel C; Wilcox WR; Yoo HW; Burlina AP; Mauer M
    Mol Genet Metab; 2023 Feb; 138(2):106967. PubMed ID: 36709533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.
    Pisani A; Spinelli L; Sabbatini M; Andreucci MV; Procaccini D; Abbaterusso C; Pasquali S; Savoldi S; Comotti C; Cianciaruso B
    Am J Kidney Dis; 2005 Jul; 46(1):120-7. PubMed ID: 15983965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fabry disease in Italy: first epidemiologic and collaborative study].
    Ricci R; Castorina M; Di Lillo M; Antuzzi D; Frustaci A; Parini R; Menni F; Furlan F; Burlina A; Burlina A; Catuogno S; Gabrielli O; Burattini I; Borsini W; Buchner S; Ferriozzi S; Spisni C; De Vito R; Di Rocco M; Aricò M; Pistone G; Bongiorno AM; Morrone A; Cavicchi C; Zammarchi E
    Ann Ital Med Int; 2004; 19(4):269-75. PubMed ID: 15678707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical courses of two male siblings on hemodialysis for Fabry disease ].
    Itoh K; Tanaka M; Matsushita K; Miyamura N; Nishida K; Araki E; Nonoguchi H; Tomita K
    Nihon Jinzo Gakkai Shi; 2005; 47(2):121-7. PubMed ID: 15859134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey.
    Lidove O; Ramaswami U; Jaussaud R; Barbey F; Maisonobe T; Caillaud C; Beck M; Sunder-Plassmann G; Linhart A; Mehta A;
    Int J Clin Pract; 2006 Sep; 60(9):1053-9. PubMed ID: 16939546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry.
    Politei JM; Cabrera G; Amartino H; Valdez R; Masllorens F; Ripeau D; Antongiovanni N; Soliani A; Luna P; Cedrolla M; Fernandez S; Fainboim A
    Int J Clin Pract; 2013 Jan; 67(1):66-72. PubMed ID: 23241050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
    Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.
    Üçeyler N; He L; Schönfeld D; Kahn AK; Reiners K; Hilz MJ; Breunig F; Sommer C
    J Peripher Nerv Syst; 2011 Dec; 16(4):304-14. PubMed ID: 22176145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey.
    Ramaswami U; Parini R; Pintos-Morell G; Kalkum G; Kampmann C; Beck M;
    Clin Genet; 2012 May; 81(5):485-90. PubMed ID: 21457233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fabry disease: cardiac manifestations and therapeutic options.
    Pierre-Louis B; Kumar A; Frishman WH
    Cardiol Rev; 2009; 17(1):31-5. PubMed ID: 19092368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
    Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
    Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cardiological follow-up in patients with Fabry disease].
    Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
    G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive clinical evaluation of a large Spanish family with Anderson-Fabry disease, novel GLA mutation and severe cardiac phenotype.
    San Román-Monserrat I; Moreno-Flores V; López-Cuenca D; Rodríguez-González-Herrero E; Guillén-Navarro E; Rodríguez-González-Herrero B; Alegría-Fernández M; Poza-Cisneros G; Piñero-Fernández JA; Sornichero-Martínez J; Gimeno-Blanes JR
    Med Clin (Barc); 2014 Jun; 142(11):497-504. PubMed ID: 24679964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.
    Torvin Møller A; Winther Bach F; Feldt-Rasmussen U; Rasmussen A; Hasholt L; Lan H; Sommer C; Kølvraa S; Ballegaard M; Staehelin Jensen T
    Pain; 2009 Sep; 145(1-2):237-45. PubMed ID: 19665302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fabry disease.
    Yuasa T; Takenaka T; Higuchi K; Uchiyama N; Horizoe Y; Cyaen H; Mizukami N; Takasaki K; Kisanuki A; Miyata M; Ohishi M
    J Echocardiogr; 2017 Dec; 15(4):151-157. PubMed ID: 28674962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fabry disease and the skin: data from FOS, the Fabry outcome survey.
    Orteu CH; Jansen T; Lidove O; Jaussaud R; Hughes DA; Pintos-Morell G; Ramaswami U; Parini R; Sunder-Plassman G; Beck M; Mehta AB;
    Br J Dermatol; 2007 Aug; 157(2):331-7. PubMed ID: 17573884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The management and treatment of children with Fabry disease: A United States-based perspective.
    Hopkin RJ; Jefferies JL; Laney DA; Lawson VH; Mauer M; Taylor MR; Wilcox WR;
    Mol Genet Metab; 2016 Feb; 117(2):104-13. PubMed ID: 26546059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey.
    Ramaswami U; Whybra C; Parini R; Pintos-Morell G; Mehta A; Sunder-Plassmann G; Widmer U; Beck M;
    Acta Paediatr; 2006 Jan; 95(1):86-92. PubMed ID: 16498740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic goals in the treatment of Fabry disease.
    Mehta A; West ML; Pintos-Morell G; Reisin R; Nicholls K; Figuera LE; Parini R; Carvalho LR; Kampmann C; Pastores GM; Lidove O
    Genet Med; 2010 Nov; 12(11):713-20. PubMed ID: 20975569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anemia is a new complication in Fabry disease: data from the Fabry Outcome Survey.
    Kleinert J; Dehout F; Schwarting A; de Lorenzo AG; Ricci R; Kampmann C; Beck M; Ramaswami U; Linhart A; Gal A; Houge G; Widmer U; Mehta A; Sunder-Plassmann G
    Kidney Int; 2005 May; 67(5):1955-60. PubMed ID: 15840043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.